New investment brings LimmaTech’s series A to CHF 40 million

Emerging antimicrobial resistance worldwide presents a serious public health threat. Inappropriate or excessive use of antibiotics has resulted in a major increase in bacterial resistance against the formerly effective drugs. LimmaTech aims to address this challenge using its proprietary multi-antigen vaccine technology platform and other pathogen-specific vaccine approaches to prevent increasingly untreatable microbial infections. The company is working on specific programs addressing Staphylococcus aureus, Shigella, and sexually transmitted diseases like gonorrhea.with the goal to deliver affordable vaccine-induced protection against the increasingly untreatable microbial infections.  

Following the initial Series A closing co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund, LimmaTech has raised an additional USD 3 million from Tenmile, a health technology investment business owned by Tattarang, one of Australia’s largest private investment groups. Tenmile focuses on supporting and building early-stage companies from idea to commercialisation. The additional financial support will enable LimmaTech to advance its proprietary self-adjuvanting and multi-antigen vaccine technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections.  

This year, LimmaTech will prioritize achieving key milestones for both preclinical and clinical vaccine candidates, including initiating new Phase 1 clinical trials for their Staphylococcus aureus candidate and Phase 2 trials for the Shigella vaccine candidate. The funds will also support further developments of LimmaTech’s proprietary technology platform, as highlighted by the company's CEO Dr Franz-Werner Haas. “With LimmaTech’s robust and expanding pipeline of innovative vaccine candidates, we are pursuing a technology-agnostic approach to provide the most effective, disease-specific vaccines for combating severe pathogens that are increasingly resistant to antibiotics”, said Haas.

(press release / SR)